BioSpace News Archive

“By putting intuitive tools in the hands of people everywhere, we can advance science and improve lives faster, together.”

New Representation from Edwards Lifesciences and Additions to CLSA Executive Committee Also Announced

Holsworth to lead clinical research efforts and product development of new CBD solutions

PhosphorusONE is the third test approved for Phosphorus in the state in the past three months.

Leading Acne Brand Aims to Educate Consumers About the Acne-Fighting Benefits of Retinoids

“The Sounds of Tinnitus” campaign launches with a four-minute video that shares the sounds and personal struggles of real people suffering from the condition.

Mr. Feher will initially focus on the development of financial and operational capabilities, as well as creating value for the organization through the execution of company’s strategy.

Ryan Rothacker joins the Company from MBRE Healthcare, where he served as Senior Vice President, Asset Management.

The National Institutes of Health has awarded researchers at Geisinger $3.1 million over the next five years to explore innovative approaches for early, genomics-based detection of arrhythmogenic right ventricular cardiomyopathy (ARVC).

FDA’s approval of ketamine to address depression classified as ‘treatment resistant’ is a double-edged sword. “Ketamine is currently used as an anesthetic, but it is also an abusable, addictive street drug,” commented Indra Cidambi, M.D., Addiction Expert and Medical Director at Center for Network Therapy (CNT)